Limits...
Lightweight Breast Implants: A Novel Solution for Breast Augmentation and Reconstruction Mammaplasty.

Govrin-Yehudain J, Dvir H, Preise D, Govrin-Yehudain O, Govreen-Segal D - Aesthet Surg J (2015)

Bottom Line: Mechanical challenges exceeding the elastic capacity of the breast tissue components, eventually lead to irreversible tissue stretching, directly proportional to the introduced mass.The CE-marked device can be effectively implanted using standard of care procedures and has been established safe for human use.In summary, this novel, lightweight breast implant promises to reduce breast tissue compromise and deformation and subsequent reoperation, further improving patient safety and satisfaction.

View Article: PubMed Central - PubMed

Affiliation: Dr Govrin-Yehudain is President, Dr Haim is Chief Technology Officer, and Mr Govreen-Segal is Chief Executive Officer, G&G Biotechnology Ltd., Haifa, Israel. Dr Govrin-Yehudain is also Founding Plastic Surgeon, Beit Harofim Medical Center, Haifa, Israel. Dr Preise is a Senior Intern in the Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel. Mr Govrin-Yehudain is a Medical Student, Bar Ilan University, Ramat Gan, Israel.

No MeSH data available.


Related in: MedlinePlus

Round and anatomical B-Lite® Lightweight Breast Implants (LWBIs). The current B-Lite® catalogue includes over 350 styles and sizes. Reprinted with permission from G&G Biotechnology Ltd., Haifa, Israel.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4622048&req=5

SJV080F2: Round and anatomical B-Lite® Lightweight Breast Implants (LWBIs). The current B-Lite® catalogue includes over 350 styles and sizes. Reprinted with permission from G&G Biotechnology Ltd., Haifa, Israel.

Mentions: Since their introduction, saline and silicone breast implant volume and weight have been synonymous (specific gravity: 1.0 g/mL and 0.97 g/mL, respectively). Recognition of the weight-dependent impact of mechanical forces on breast tissue integrity has prompted the design of the novel, fifth-generation form-stable, silicone gel B-Lite® Lightweight Breast Implant (LWBI) (G&G Biotechnology Ltd., Haifa, Israel). The round or anatomical implant (Figure 2) contains a continuous phase, reinforced, medical-grade silicone gel filler enriched with inert, high-purity, hollow, borosilicate glass microspheres chemically bound to and encapsulated by the gel network. Microsphere spatial positioning is fixed by means of a proprietary curing process. Furthermore, the microspheres are surface-treated to increase their hydrophobicity and ensure that they remain affixed within the silicone gel. The resulting high-strength bond between the microspheres and the gel is estimated to significantly exceed that of the cohesion forces within the gel, effectively creating gel-covered microspheres and obviating the risk of both free microspheres leaking from the encasing shell and/or separating from the gel. In the unlikely event of shell degradation or rupture, the gel-microsphere bond ensures bodily exposure to gel material only, as would be the case with rupture of a conventional silicone gel implant. Taken together, the unbreakable nature of the gel, the microspheres, and the microsphere-gel interactions result in an implant with a marked mechanical gel strength that is instrumental in maintaining the form and structure of the implant, resisting dispersion even in case of rupture (Figure 3). Furthermore, the microspheres are size-selected to achieve the desired spatial distribution and concentration. The strictly enforced particle size limitation (>30 µm) stymies leaching and migration through the intact shell. Likewise, in the unlikely event of the implant's rupture and direct contact of its contents with bodily tissues, the microspheres are too large to undergo phagocytosis or drainage through the lymphatic system and would, at most, only elicit a local foreign body reaction.Figure 2.


Lightweight Breast Implants: A Novel Solution for Breast Augmentation and Reconstruction Mammaplasty.

Govrin-Yehudain J, Dvir H, Preise D, Govrin-Yehudain O, Govreen-Segal D - Aesthet Surg J (2015)

Round and anatomical B-Lite® Lightweight Breast Implants (LWBIs). The current B-Lite® catalogue includes over 350 styles and sizes. Reprinted with permission from G&G Biotechnology Ltd., Haifa, Israel.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4622048&req=5

SJV080F2: Round and anatomical B-Lite® Lightweight Breast Implants (LWBIs). The current B-Lite® catalogue includes over 350 styles and sizes. Reprinted with permission from G&G Biotechnology Ltd., Haifa, Israel.
Mentions: Since their introduction, saline and silicone breast implant volume and weight have been synonymous (specific gravity: 1.0 g/mL and 0.97 g/mL, respectively). Recognition of the weight-dependent impact of mechanical forces on breast tissue integrity has prompted the design of the novel, fifth-generation form-stable, silicone gel B-Lite® Lightweight Breast Implant (LWBI) (G&G Biotechnology Ltd., Haifa, Israel). The round or anatomical implant (Figure 2) contains a continuous phase, reinforced, medical-grade silicone gel filler enriched with inert, high-purity, hollow, borosilicate glass microspheres chemically bound to and encapsulated by the gel network. Microsphere spatial positioning is fixed by means of a proprietary curing process. Furthermore, the microspheres are surface-treated to increase their hydrophobicity and ensure that they remain affixed within the silicone gel. The resulting high-strength bond between the microspheres and the gel is estimated to significantly exceed that of the cohesion forces within the gel, effectively creating gel-covered microspheres and obviating the risk of both free microspheres leaking from the encasing shell and/or separating from the gel. In the unlikely event of shell degradation or rupture, the gel-microsphere bond ensures bodily exposure to gel material only, as would be the case with rupture of a conventional silicone gel implant. Taken together, the unbreakable nature of the gel, the microspheres, and the microsphere-gel interactions result in an implant with a marked mechanical gel strength that is instrumental in maintaining the form and structure of the implant, resisting dispersion even in case of rupture (Figure 3). Furthermore, the microspheres are size-selected to achieve the desired spatial distribution and concentration. The strictly enforced particle size limitation (>30 µm) stymies leaching and migration through the intact shell. Likewise, in the unlikely event of the implant's rupture and direct contact of its contents with bodily tissues, the microspheres are too large to undergo phagocytosis or drainage through the lymphatic system and would, at most, only elicit a local foreign body reaction.Figure 2.

Bottom Line: Mechanical challenges exceeding the elastic capacity of the breast tissue components, eventually lead to irreversible tissue stretching, directly proportional to the introduced mass.The CE-marked device can be effectively implanted using standard of care procedures and has been established safe for human use.In summary, this novel, lightweight breast implant promises to reduce breast tissue compromise and deformation and subsequent reoperation, further improving patient safety and satisfaction.

View Article: PubMed Central - PubMed

Affiliation: Dr Govrin-Yehudain is President, Dr Haim is Chief Technology Officer, and Mr Govreen-Segal is Chief Executive Officer, G&G Biotechnology Ltd., Haifa, Israel. Dr Govrin-Yehudain is also Founding Plastic Surgeon, Beit Harofim Medical Center, Haifa, Israel. Dr Preise is a Senior Intern in the Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel. Mr Govrin-Yehudain is a Medical Student, Bar Ilan University, Ramat Gan, Israel.

No MeSH data available.


Related in: MedlinePlus